The ‘LMRT Lab’ Where Biology Is Treated Like an Engineering System
Sangeeta Bhatia stands at the forefront of biomedical engineering, blending miniaturization from computing with biology to revolutionize diagnostics, drug testing, and therapies for cancer, liver disease, and infections. As Director of MIT’s Laboratory for Multiscale Regenerative Technologies (LMRT) and the Marble Center for Cancer Nanomedicine, her innovations have spawned over 65 patents, more than 70 commercial products, and eight biotech startups.
If you are thinking about applying to Sangeeta Bhatia’s lab, the first thing you should know is this: this is not a traditional biology lab. It is also not a traditional engineering lab. It sits somewhere in between, and that is exactly why it is so influential.
Sangeeta Bhatia is a physician and biomedical engineer at MIT. She leads the Laboratory for Multiscale Regenerative Technologies (LMRT). Her work spans tissue engineering, nanotechnology, disease sensing, and regenerative medicine. But if you look closely, you will notice that the real theme is much simpler. Her lab is trying to answer one big question: can we engineer biological systems the same way we engineer devices?
That idea sounds simple, but it changes how you design experiments, how you think about disease, and how you plan your career as a scientist.
The Core Scientific Thinking of Sangeeta Bhatia’s Lab
Most biology research tries to observe what disease is doing. Her lab often tries to build tools that interact with disease and force it to reveal information. This is why her projects often look unusual. You might see engineered liver tissues, nanoparticles that generate diagnostic signals, or tissue models designed to behave like real organs.
The goal is always to make biology more predictable and measurable. This mindset is very important if you plan to work in translational medicine or medical technology.
How She Became Known: Tissue Engineering and the Microliver
Early in her career, Bhatia worked on a major problem in drug development. Liver cells quickly lose function when removed from the body. That meant drug toxicity testing was often unreliable. Her lab solved this by controlling how liver cells are arranged and supported at the microscale level.
A key paper that defined this field was published in Nature Biotechnology in 2008 by Khetani and Bhatia. This work showed that liver cells behave much better when placed in engineered microenvironments with supporting cells. Today, many organ-on-chip technologies are conceptually built on this idea.
If you join her lab, you will quickly learn that cells are not only controlled by genes and signaling molecules. They are also controlled by physical structure, spatial organization, and mechanical environment. This is a very engineering way of thinking about biology.
The Shift Toward Nanotechnology and Synthetic Biomarkers
Later, her lab moved into nanotechnology and disease sensing. Instead of waiting for disease biomarkers to appear naturally, her group started building nanoparticles that create detectable signals when they encounter disease activity.
One landmark paper from this area was published in Nature Biotechnology in 2013 by Kwong and colleagues. This work showed that engineered nanoparticles could produce disease-specific signals that can be detected in urine. It was one of the first clear demonstrations that diagnostic signals could be engineered rather than passively measured.
Many synthetic biomarker ideas still fail during clinical translation. The biology is complex, and real patients are not controlled systems.
For many trainees, this is where the lab becomes exciting. You are not just studying biology. You are designing systems that interact with biology inside the body. That requires comfort with materials science, molecular biology, and clinical thinking at the same time.
Disease Modeling: Why Her Lab Does Not Focus on One Disease
Another thing that surprises many applicants is that her lab does not focus on only cancer, or only liver disease, or only infection. Instead, the lab focuses on biological principles that apply across diseases.
Her lab has worked on tumor microenvironments, liver infection models, and host-pathogen interactions. For example, engineered liver models have been used to study malaria infection biology in ways that are not possible with simple cell culture.
This tells you something important about how the lab thinks. They care less about disease labels and more about biological mechanisms. If you like mechanism-driven science, this environment can be very stimulating.
The Move Toward Regenerative Medicine
In recent years, her lab has pushed further into regenerative medicine. The goal is not only to model organs but to eventually support or replace failing biological functions.
A good example is the vascularized liver model published in PNAS in 2022. This work showed how engineered tissues can mimic regeneration processes. It is not full organ replacement yet, but it is a step toward that direction.
This work connects disease modeling, tissue engineering, and therapy development into one pipeline. Very few labs operate across all these levels at once.
Her Scientific Philosophy (What You Will Feel If You Join)
Bhatia strongly believes that biology can be engineered. She also believes that the best scientific problems exist between disciplines, not inside them. Many of her projects start with a real clinical or biological problem and then ask what engineering tool is needed to solve it.
She is also very translation-focused. Many projects are designed with eventual clinical or commercial use in mind. That does not mean the science is less fundamental. It just means the lab is always thinking about real-world impact.
How She Runs the Lab
From talks, interviews, and trainee experiences, her lab culture is collaborative and interdisciplinary. She tends to hire people who are curious and willing to learn outside their original field.
The lab is known for high intellectual expectations, but not for promoting unhealthy overwork culture. Communication across disciplines is very important. A biologist is expected to understand some engineering logic, and an engineer is expected to understand biological complexity. If medicine becomes engineerable, labs like this are where that future is being designed.
Funding and Why It Matters for Applicants
Her research has historically been supported by major funding bodies such as the NIH and HHMI, along with cancer research foundations, translational innovation grants, and industry collaborations. She is also strongly connected to the biotech translation ecosystem through startups and partnerships.
For a trainee, this usually means access to advanced tools, stable funding, and strong collaboration networks. It also means projects often sit at the boundary of academia and industry.
Engineering as a Language for Biology
Bhatia’s biggest contribution may not be any single technology — it may be a way of thinking.
Her work shows that:
Biology can be engineered with precision
Disease detection can be designed, not just discovered
Tissue models can replace poor animal or cell models
Diagnostics, therapy, and modeling are interconnected
Sangeeta Bhatia represents a shift in how biomedical science is done. Instead of asking only how biology works, her lab often asks how biology can be redesigned or controlled using engineering principles.
If medicine is moving toward engineered biological systems, labs like this are helping build that future.